The Technical AnalystExchange: CPH Sector: Healthcare Industry: Biotechnology
Genmab A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.69% DKK1 956.50
America/New_York / 30 apr 2024 @ 10:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127 914 mill |
| EPS: | 66.06 |
| P/E: | 29.62 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 65.38 mill |
| Avg Daily Volume: | 0.128 mill |
| RATING 2024-04-30 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.62x |
| Company: PE 29.62 | sector: PE 47.95 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.73x |
| Company: PE 29.62 | industry: PE 40.56 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
DKK1 951.16 (-0.27%) DKK-5.34 |
| Date: 2024-04-30 |
| Expected Trading Range (DAY) |
|---|
|
DKK 1 899.79 - 2 013.21 ( +/- 2.90%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | DKK1 956.50 (-0.69% ) |
| Volume | 0.120 mill |
| Avg. Vol. | 0.128 mill |
| % of Avg. Vol | 93.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GMAB.CO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GMAB.CO
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.